Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia.
作者信息
Yates Bonnie, Hoang Chloe N, Gava Flavia, Giordani Victoria M, Little Lauren, Epstein Monica, Brems Jillian, McGrath Casey, Foley Toni, Shalabi Haneen, Shah Nirali N
机构信息
Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
出版信息
Blood Immunol Cell Ther. 2025 Sep;1(2). doi: 10.1016/j.bict.2025.100008. Epub 2025 Aug 12.
Abstract
摘要
相似文献
1
Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia.B细胞急性淋巴细胞白血病儿童和青年接受嵌合抗原受体T细胞疗法和造血干细胞移植后的迟发效应
Blood Immunol Cell Ther. 2025 Sep;1(2). doi: 10.1016/j.bict.2025.100008. Epub 2025 Aug 12.
2
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia.INSPIRED 研讨会第 2 部分：嵌合抗原受体 T 细胞疗法治疗 B 细胞急性淋巴细胞白血病后预防和管理复发。
Transplant Cell Ther. 2023 Nov;29(11):674-684. doi: 10.1016/j.jtct.2023.08.030. Epub 2023 Sep 9.
3
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.针对CD19导向免疫治疗后复发的B细胞急性淋巴细胞白血病儿童和成人的CD22靶向嵌合抗原受体修饰T细胞
J Immunother Cancer. 2025 Apr 17;13(4):e011549. doi: 10.1136/jitc-2025-011549.
4
Brain MRI changes in children and young adults with B-cell acute lymphoblastic leukemia following chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法后B细胞急性淋巴细胞白血病儿童和年轻成人的脑磁共振成像变化
Eur Radiol. 2025 Mar 20. doi: 10.1007/s00330-025-11515-2.
5
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.CD19CAR T 细胞治疗缓解后的复发/难治性 B-ALL 成人患者行首次和二次同种异体移植巩固治疗。
Transplant Cell Ther. 2024 Aug;30(8):788.e1-788.e9. doi: 10.1016/j.jtct.2024.06.013. Epub 2024 Jun 12.
6
Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia.嵌合抗原受体 T 细胞疗法的作用：在小儿急性淋巴细胞白血病中桥接移植或独立治疗。
Curr Opin Hematol. 2021 Nov 1;28(6):373-379. doi: 10.1097/MOH.0000000000000685.
7
INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia.INSPIRED 研讨会第 4A 部分：为 B 细胞急性淋巴细胞白血病的特殊人群提供嵌合抗原受体 T 细胞疗法。
Transplant Cell Ther. 2024 Jan;30(1):56-70. doi: 10.1016/j.jtct.2023.10.005. Epub 2023 Oct 10.
8
INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.INSPIRED 研讨会第 1 部分：嵌合抗原受体 T 细胞治疗 B 细胞急性淋巴细胞白血病患儿和青年患者的临床变量与改善结局的关系。
Transplant Cell Ther. 2023 Oct;29(10):598-607. doi: 10.1016/j.jtct.2023.07.016. Epub 2023 Jul 20.
9
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia.外周血计数低和促炎细胞因子升高提示急性淋巴细胞白血病患者CD19嵌合抗原受体T细胞反应不佳。
Transplant Cell Ther. 2025 May 20. doi: 10.1016/j.jtct.2025.05.003.
10
CAR T-cells for acute leukemias in children: current status, challenges, and future directions.用于儿童急性白血病的嵌合抗原受体T细胞：现状、挑战及未来方向
Cancer Metastasis Rev. 2025 Apr 23;44(2):47. doi: 10.1007/s10555-025-10261-7.
本文引用的文献
1
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.应用 CAR-T 后 EHA/EBMT 分级评估 ICAHT：感染和死亡率的比较发生率和相关性。
Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767.
2
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.儿童和青年急性淋巴细胞白血病患者接受 tisagenlecleucel 治疗后，微小残留病的下一代测序预测复发。
Blood Cancer Discov. 2022 Jan;3(1):66-81. doi: 10.1158/2643-3230.BCD-21-0095. Epub 2021 Dec 1.
3
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.CD19 嵌合抗原受体 T 细胞诱导缓解后行造血干细胞移植可带来无白血病生存优势。
Transplant Cell Ther. 2022 Jan;28(1):21-29. doi: 10.1016/j.jtct.2021.10.003. Epub 2021 Oct 10.
4
Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms.血液恶性肿瘤造血干细胞移植后神经认知障碍：表型与机制。
Oncologist. 2021 Nov;26(11):e2021-e2033. doi: 10.1002/onco.13867. Epub 2021 Jul 12.
5
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.儿童和青少年 B 细胞急性淋巴细胞白血病患者接受 CD19-CAR T 细胞治疗的长期随访。
J Clin Oncol. 2021 May 20;39(15):1650-1659. doi: 10.1200/JCO.20.02262. Epub 2021 Mar 25.
6
Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report.异基因造血干细胞移植治疗儿童急性淋巴细胞白血病后肝内胆管细胞癌：一例罕见的继发恶性肿瘤病例报告。
Pediatr Transplant. 2020 Mar;24(2):e13653. doi: 10.1111/petr.13653. Epub 2020 Jan 16.
7
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.嵌合抗原受体 T 细胞治疗后长期生存者的患者报告神经精神结局。
Biol Blood Marrow Transplant. 2020 Jan;26(1):34-43. doi: 10.1016/j.bbmt.2019.09.037. Epub 2019 Oct 9.
8
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
9
Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.青少年或青年期接受治疗的霍奇金淋巴瘤幸存者发生第二原发恶性肿瘤的长期风险。
J Clin Oncol. 2000 Feb;18(3):487-97. doi: 10.1200/JCO.2000.18.3.487.
10
Identification of a new hereditary amyloidosis prealbumin variant, Tyr-77, and detection of the gene by DNA analysis.一种新的遗传性淀粉样变性前白蛋白变体Tyr-77的鉴定及通过DNA分析对该基因的检测。
J Clin Invest. 1988 Jan;81(1):189-93. doi: 10.1172/JCI113293.
Zotero 插件